A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy.

Rubicon Research Repository/Manakin Repository

A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy.

Show simple item record


dc.contributor.author Heys, SD
dc.contributor.author Smith, IC
dc.contributor.author Ross, JA
dc.contributor.author Gilbert, FJ
dc.contributor.author Brooks, J
dc.contributor.author Semple, S
dc.contributor.author Miller, ID
dc.contributor.author Hutcheon, A
dc.contributor.author Sarkar, T
dc.contributor.author Eremin, O
dc.date.accessioned 2007-11-21T01:13:31Z
dc.date.available 2007-11-21T01:13:31Z
dc.date.issued 2006
dc.identifier.citation Undersea Hyperb Med. 2006 Jan-Feb;33(1):33-43. en
dc.identifier.other 16602255
dc.identifier.uri http://archive.rubicon-foundation.org/5012
dc.description Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc. en
dc.description.abstract Work in an animal cancer model suggests that pretreatment with hyperbaric oxygen can improve tumor vascularity rendering chemotherapy more effective. Accordingly 32 subjects with locally advanced breast carcinoma (>5cm diameter) entered into a randomized clinical trial where a course was administered of six intravenous pulses of cyclophosphamide 1000mg/m2 i.v., doxorubicin 50mg/m2 i.v. and vincristine 1.5mg/m2 i.v. In the case group this was preceded by ten, once daily, sessions of hyperbaric oxygen therapy (HBO2) administered either at 2.4 or 2.0 atmospheres absolute. Eleven out of 15 subjects tolerated a full course of HBO2 and chemotherapy. All 17 control subjects tolerated a full course of chemotherapy. Tumor extravascular extracellular or edema fluid was reduced after HBO2 but there was no reduction in tumor cell volume and no indication of increased vascularity on MRI. Clinical and pathological responses to chemotherapy were the same in both groups and there was no evidence of neovascularisation. Five year survival in those who tolerated the trial regime was 73% and did not differ between the groups. This mortality was cancer related. en
dc.format.extent 450059 bytes
dc.format.mimetype application/pdf
dc.language.iso en en
dc.publisher Undersea and Hyperbaric Medical Society, Inc. en
dc.subject Hyperbaric Oxygenation en
dc.subject neovascularisation en
dc.subject animal en
dc.subject cancer en
dc.subject tumor en
dc.subject breast en
dc.subject chemotherapy en
dc.subject DRUGS en
dc.subject Randomized Controlled Trial en
dc.subject human en
dc.subject.mesh Randomized Controlled Trial Research Support, Non-U.S. Gov't MeSH Terms: Adult Aged Antineoplastic Combined Chemotherapy Protocols/therapeutic use* Breast Neoplasms/blood supply Breast Neoplasms/drug therapy Breast Neoplasms/therapy* Capillary Permeability Chemotherapy, Adjuvant Combined Modality Therapy/methods Cyclophosphamide/administration & dosage Doxorubicin/administration & dosage Female Follow-Up Studies Humans Hyperbaric Oxygenation/methods* Middle Aged Neovascularization, Pathologic/prevention & control Pilot Projects Vincristine/administration & dosage Substances: Doxorubicin Cyclophosphamide Vincristine en
dc.title A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy. en
dc.type Article en

Files in this item

Files Size Format View
16602255.pdf 439.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

Browse

My Account